Analysts Set Fractyl Health, Inc. (NASDAQ:GUTS) PT at $5.12

Fractyl Health, Inc. (NASDAQ:GUTS) has earned an average recommendation of “Moderate Buy” from the six analysts that are covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and four have given a buy recommendation to the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $5.12.

Several equities analysts have commented on the company. Wall Street Zen upgraded Fractyl Health from a “strong sell” rating to a “hold” rating in a report on Saturday, May 16th. Weiss Ratings upgraded Fractyl Health from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, July 6th. HC Wainwright reissued a “buy” rating and set a $8.00 price target on shares of Fractyl Health in a research report on Thursday, June 4th. Finally, Craig Hallum started coverage on Fractyl Health in a research report on Wednesday, July 1st. They issued a “buy” rating and a $4.00 target price on the stock.

Fractyl Health Stock Down 1.1%

Fractyl Health stock opened at $0.68 on Thursday. The company has a 50-day simple moving average of $0.78 and a 200-day simple moving average of $0.74. The company has a debt-to-equity ratio of 1.41, a quick ratio of 4.28 and a current ratio of 4.28. The firm has a market capitalization of $107.44 million, a P/E ratio of -0.52 and a beta of 2.32. Fractyl Health has a one year low of $0.38 and a one year high of $2.44.

Fractyl Health (NASDAQ:GUTS) last released its quarterly earnings results on Tuesday, May 12th. The company reported $0.06 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.23. As a group, equities analysts expect that Fractyl Health will post -0.6 earnings per share for the current year.

Insider Activity

In other news, Director William Bradley acquired 68,493 shares of Fractyl Health stock in a transaction on Wednesday, June 10th. The shares were purchased at an average cost of $0.73 per share, for a total transaction of $49,999.89. Following the completion of the purchase, the director directly owned 84,622 shares of the company’s stock, valued at approximately $61,774.06. This represents a 424.66% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Ian Sheffield bought 35,000 shares of the stock in a transaction on Wednesday, June 10th. The shares were acquired at an average cost of $0.73 per share, with a total value of $25,550.00. Following the purchase, the director owned 35,000 shares of the company’s stock, valued at approximately $25,550. This represents a ∞ increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have purchased 171,493 shares of company stock valued at $127,150 in the last ninety days. 8.52% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of GUTS. Woodline Partners LP boosted its position in shares of Fractyl Health by 47.2% during the 1st quarter. Woodline Partners LP now owns 516,921 shares of the company’s stock worth $615,000 after purchasing an additional 165,786 shares in the last quarter. Qube Research & Technologies Ltd bought a new position in shares of Fractyl Health during the 2nd quarter worth $129,000. General Catalyst Group Management LLC purchased a new position in shares of Fractyl Health in the second quarter valued at $7,912,000. Jane Street Group LLC bought a new stake in Fractyl Health during the second quarter valued at $31,000. Finally, Osaic Holdings Inc. lifted its position in Fractyl Health by 460.3% during the second quarter. Osaic Holdings Inc. now owns 59,645 shares of the company’s stock valued at $97,000 after purchasing an additional 49,000 shares during the last quarter.

Fractyl Health Company Profile

Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.